Novo Nordisk, obesity and Weight-Loss Drug

Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk Is Falling. Compeitition Is a Killer.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results
Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price
Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers chase market share.
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Shares in Roche rallied in Europe, while Zealand stock surged around 30%.
Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market. Lisa Bernhard has more.
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

Novo Nordisk Skeptic Finally Upgrades Stock

Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Zacks.com on MSN19h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...